+49 711 500 989 80
deen

Bone marrow cancer: Potential drug targets



Bone marrow cancer: Potential drug targets

New research finds that patients with ASXL1-mutant chronic myelomonocytic leukemia — an uncommon type of cancer of the bone marrow — have distinctive epigenetic changes that can activate harmful genes and cause the cancer to grow faster. The ASXL1 genetic mutation also can transform the disease into the more aggressive acute myeloid leukemia.

Materials provided by Mayo Clinic. Original written by Susan Murphy. Note: Content may be edited for style and length.




Source link aaaaa

Related posts

27th September 2022

Rhombic lip implicated in origins of high-risk medulloblastoma

Read more
27th September 2022

How prostate cancer may begin

Read more
27th September 2022

Diets rich in refined fiber may increase liver cancer risk in some individuals

Read more